BOT - Anything but charting, page-9802

Look, I'm just as hopeful as you that BOT get taken out soon enough for a hefty price tag. And whilst the market certainly isn't as simple as timing sales data, I'm just seeing that the price is steadily growing as we move towards sales, and hasn't gone ballistic expecting +$200m/yr income. Maybe big pharma will wake up to the opportunity that all of us punters can clearly see, but obviously of which BP's droves of analysts are missing, hence no offer yet. Or maybe, BP are waiting to see some certainty in sales. I truly do hope BOT are negotiating some sort of deal with BP as we speak, and that we will all be very pleasantly surprised!